Geode Capital Management LLC Buys New Holdings in Atyr PHARMA INC (NASDAQ:ATYR)

Geode Capital Management LLC acquired a new stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 891,407 shares of the company's stock, valued at approximately $3,229,000. Geode Capital Management LLC owned approximately 1.06% of Atyr PHARMA as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its position in Atyr PHARMA by 467.8% during the fourth quarter. JPMorgan Chase & Co. now owns 178,532 shares of the company's stock worth $646,000 after buying an additional 147,092 shares in the last quarter. American Century Companies Inc. acquired a new stake in shares of Atyr PHARMA in the 4th quarter worth $319,000. Kingswood Wealth Advisors LLC purchased a new position in shares of Atyr PHARMA during the 4th quarter worth $170,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Atyr PHARMA during the 4th quarter valued at about $144,000. Finally, D.A. Davidson & CO. purchased a new stake in shares of Atyr PHARMA in the fourth quarter valued at about $141,000. Institutional investors and hedge funds own 61.72% of the company's stock.

Atyr PHARMA Trading Down 3.7 %

NASDAQ:ATYR traded down $0.13 during trading hours on Thursday, reaching $3.34. 1,042,945 shares of the stock were exchanged, compared to its average volume of 903,035. Atyr PHARMA INC has a twelve month low of $1.42 and a twelve month high of $4.66. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The business has a 50-day moving average of $3.31 and a two-hundred day moving average of $3.38. The company has a market capitalization of $296.79 million, a price-to-earnings ratio of -3.55 and a beta of 0.95.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last posted its earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. On average, equities analysts predict that Atyr PHARMA INC will post -0.91 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on ATYR shares. Leerink Partners assumed coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 target price on the stock. Cantor Fitzgerald started coverage on Atyr PHARMA in a research report on Monday, January 6th. They issued an "overweight" rating for the company. HC Wainwright restated a "buy" rating and issued a $35.00 target price on shares of Atyr PHARMA in a research report on Friday, March 14th. Finally, Leerink Partnrs upgraded Atyr PHARMA to a "strong-buy" rating in a report on Tuesday, February 18th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $18.60.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.